Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRX002-01 phase I intrapleural natural-type microRNA replacement therapy study in malignant pleural mesothelioma
jRCT2061210058Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2021
- Modality
- miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, miRNA Inhibitors → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MIRX002 in pleural mesothelioma, sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety and tolerability and Dose-limiting toxicity. Started Dec 2021; status: completed.
02
Drugs
MIRX002
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2061210058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210058.